课题基金 / 基金详情

A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma

A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
在不适合移植的新诊断多发性骨髓瘤老年人中进行固定持续时间 Daratumumab 与连续 Daratumumab 的 III 期非劣效随机对照试验 (RCT)
批准号：
478153
负责人：
Hay Annette
金额：
$222.64万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-03-01 至 2031-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=478153&lang=en
关键词：
De-Escalation Economic Analysis Multiple Myeloma Quality Of Life Randomized Phase Iii Trial

项目摘要

项目成果

Hay Annette的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Multiple myeloma (MM) is a cancer of the blood. It can lead to many problems, including kidney failure, bone damage, and low blood counts. Treatment for MM has improved greatly over the past 10 years with many new drugs being approved. One specific drug c
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Canadian Cell Therapies Workshop 2019
海外基金